Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gammaitoni

Showing results (51-60 of 230) with videos related to

Pageof 23
Sort By:
Pain Medicine (Malden, Mass.)|April 22, 2004
Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trialNathaniel P Katz, Arnold R Gammaitoni, Matthew W Davis, et al.
Epilepsy & Behavior : E&B|January 10, 2022
Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivoParthena Martin, Tangui Maurice, Arnold Gammaitoni, et al.
Immunotherapy|August 28, 2015
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectivesLidia Giraudo, Loretta Gammaitoni, Michela Cangemi, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|February 4, 2021
Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practiceJoseph Sullivan, M Scott Perry, James W Wheless, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 20, 2018
A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
Brooks Boyd, Steven Smith, Arnold Gammaitoni, et al.
BMC Musculoskeletal Disorders|July 20, 2011
Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitisPaul M Peloso, Arnold Gammaitoni, Steven S Smugar, et al.
Pain|September 3, 2010
Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trialsAndrew R Moore, Steven S Smugar, Hongwei Wang, et al.
EES Batteries|October 24, 2025
Spray-dried hard carbon-Sn composites for energy-dense Na-ion batteriesGiovanni Gammaitoni, Gihoon Cha, Rajkumar Reddy Kolan, et al.
Mitochondrion|November 14, 2022
The impact of TK2 deficiency syndrome and its treatment by nucleoside therapy on quality of lifeDagmar Amtmann, Arnold R Gammaitoni, Bradley S Galer, et al.
Pain Medicine (Malden, Mass.)|February 22, 2011
Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placeboClifton O Bingham, Steven S Smugar, Hongwei Wang, et al.
Pageof 23

Showing results (51-60 of 230) with videos related to

Sort By:
Pageof 23
Pain Medicine (Malden, Mass.)|April 22, 2004
Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trialNathaniel P Katz, Arnold R Gammaitoni, Matthew W Davis, et al.
Epilepsy & Behavior : E&B|January 10, 2022
Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivoParthena Martin, Tangui Maurice, Arnold Gammaitoni, et al.
Immunotherapy|August 28, 2015
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectivesLidia Giraudo, Loretta Gammaitoni, Michela Cangemi, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|February 4, 2021
Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practiceJoseph Sullivan, M Scott Perry, James W Wheless, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 20, 2018
A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
Brooks Boyd, Steven Smith, Arnold Gammaitoni, et al.
BMC Musculoskeletal Disorders|July 20, 2011
Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitisPaul M Peloso, Arnold Gammaitoni, Steven S Smugar, et al.
Pain|September 3, 2010
Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trialsAndrew R Moore, Steven S Smugar, Hongwei Wang, et al.
EES Batteries|October 24, 2025
Spray-dried hard carbon-Sn composites for energy-dense Na-ion batteriesGiovanni Gammaitoni, Gihoon Cha, Rajkumar Reddy Kolan, et al.
Mitochondrion|November 14, 2022
The impact of TK2 deficiency syndrome and its treatment by nucleoside therapy on quality of lifeDagmar Amtmann, Arnold R Gammaitoni, Bradley S Galer, et al.
Pain Medicine (Malden, Mass.)|February 22, 2011
Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placeboClifton O Bingham, Steven S Smugar, Hongwei Wang, et al.
Pageof 23